1
|
Peron G, Mastinu A, Peña-Corona SI, Hernández-Parra H, Leyva-Gómez G, Calina D, Sharifi-Rad J. Silvestrol, a potent anticancer agent with unfavourable pharmacokinetics: Current knowledge on its pharmacological properties and future directions for the development of novel drugs. Biomed Pharmacother 2024; 177:117047. [PMID: 38959604 DOI: 10.1016/j.biopha.2024.117047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2024] [Revised: 06/14/2024] [Accepted: 06/25/2024] [Indexed: 07/05/2024] Open
Abstract
Cancer remains a leading cause of death, with increasing incidence. Conventional treatments offer limited efficacy and cause significant side effects, hence novel drugs with improved pharmacological properties and safety are required. Silvestrol (SLV) is a flavagline derived from some plants of the Aglaia genus that has shown potent anticancer effects, warranting further study. Despite its efficacy in inhibiting the growth of several types of cancer cells, SLV is characterized by an unfavorable pharmacokinetics that hamper its use as a drug. A consistent research over the recent years has led to develop novel SLV derivatives with comparable pharmacodynamics and an ameliorated pharmacokinetic profile, demonstrating potential applications in the clinical management of cancer. This comprehensive review aims to highlight the most recent data available on SLV and its synthetic derivatives, addressing their pharmacological profile and therapeutic potential in cancer treatment. A systematic literature review of both in vitro and in vivo studies focusing on anticancer effects, pharmacodynamics, and pharmacokinetics of these compounds is presented. Overall, literature data highlight that rationale chemical modifications of SLV are critical for the development of novel drugs with high efficacy on a broad variety of cancers and improved bioavailability in vivo. Nevertheless, SLV analogues need to be further studied to better understand their mechanisms of action, which can be partially different to SLV. Furthermore, clinical research is still required to assess their efficacy in humans and their safety.
Collapse
Affiliation(s)
- Gregorio Peron
- Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, Brescia 25123, Italy.
| | - Andrea Mastinu
- Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, Brescia 25123, Italy
| | - Sheila I Peña-Corona
- Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, Mexico
| | - Hector Hernández-Parra
- Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, Mexico; Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Ciudad de México, Mexico
| | - Gerardo Leyva-Gómez
- Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, Mexico
| | - Daniela Calina
- Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova 200349, Romania.
| | - Javad Sharifi-Rad
- Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Republic of Korea; Centro de Estudios Tenológicos y Universitarios del Golfo, Veracruz, Mexico.
| |
Collapse
|
2
|
Biedermann N, Schnizer J, Lager D, Schnürch M, Stanetty C. Indium-Mediated Acyloxyallylation-Based Synthesis of Galacto-Configured Higher-Carbon Sugar Alcohols as Potential Phase Change Materials. J Org Chem 2024; 89:5573-5588. [PMID: 38578036 DOI: 10.1021/acs.joc.4c00067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/06/2024]
Abstract
Sugar alcohols fulfilling specific structural requirements are a substance class with great potential as organic phase change materials (PCMs). Within this work, we demonstrate the indium-mediated acyloxyallylation (IMA) as a useful strategy for the synthesis of higher-carbon sugar alcohols of the galacto-family featuring all hydroxyl groups in a 1,3-anti-relationship with three major synthetic achievements: first, the dihydroxylation of the IMA-derived allylic sugar derivates was systematically studied in terms of diastereoselectivity, revealing a high degree of substrate control toward anti-addition. Second, we demonstrated the use of a "double Mitsunobu" reaction, inverting the stereochemistry of terminal diols. Third, the IMA toolbox was expanded to accomplish the synthesis of derivatives with up to 10 carbon atoms from particularly unreactive aldoses. Thermal investigations of all synthesized sugar alcohols, including examples with exclusive 1,3-anti- and suboptimal 1,3-syn-relationships as well as even and odd numbers of carbon atoms, were performed. We observed clear trends in melting points and thermal storage densities and discovered limitations of organic substances in this class with melting points above 240 °C as PCMs in terms of thermal stability. With our study, we provide insights into the dependence of thermal properties on structural features, thus contributing to further understanding of organic PCMs for thermal energy storage applications.
Collapse
Affiliation(s)
- Nina Biedermann
- Institute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9/163, 1060 Vienna, Austria
| | - Julian Schnizer
- Institute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9/163, 1060 Vienna, Austria
| | - Daniel Lager
- Energy Department, AIT Austrian Institute of Technology GmbH, Giefinggasse 2, 1210 Vienna, Austria
| | - Michael Schnürch
- Institute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9/163, 1060 Vienna, Austria
| | - Christian Stanetty
- Institute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9/163, 1060 Vienna, Austria
| |
Collapse
|
3
|
Agarwal G, Chang LS, Soejarto DD, Kinghorn AD. Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species. PLANTA MEDICA 2021; 87:937-948. [PMID: 33784769 PMCID: PMC8481333 DOI: 10.1055/a-1401-9562] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
With about 120 species, Aglaia is one of the largest genera of the plant family Meliaceae (the mahogany plants). It is native to the tropical rainforests of the Indo-Australian region, ranging from India and Sri Lanka eastward to Polynesia and Micronesia. Various Aglaia species have been investigated since the 1960s for their phytochemical constituents and biological properties, with the cyclopenta[b]benzofurans (rocaglates or flavaglines) being of particular interest. Phytochemists, medicinal chemists, and biologists have conducted extensive research in establishing these secondary metabolites as potential lead compounds with antineoplastic and antiviral effects, among others. The varied biological properties of rocaglates can be attributed to their unusual structures and their ability to act as inhibitors of the eukaryotic translation initiation factor 4A (eIF4A), affecting protein translation. The present review provides an update on the recently reported phytochemical constituents of Aglaia species, focusing on rocaglate derivatives. Furthermore, laboratory work performed on investigating the biological activities of these chemical constituents is also covered.
Collapse
Affiliation(s)
- Garima Agarwal
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States
| | - Long-Sheng Chang
- Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute, Nationwide Children’s Hospital, Columbus, Ohio, United States
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, United States
- Department of Otolaryngology-Head and Neck Surgery, The Ohio State University College of Medicine, Columbus, Ohio, United States
- Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio, United States
| | - Djaja Doel Soejarto
- College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, United States
- Science and Education, Field Museum, Chicago, Illinois, United States
| | - A. Douglas Kinghorn
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States
| |
Collapse
|
4
|
Frontier AJ, Sinclair PP. Merging Strategy, Improvisation, and Conversation to Solve Problems in Target Synthesis. Acc Chem Res 2021; 54:1817-1829. [PMID: 33705115 DOI: 10.1021/acs.accounts.0c00804] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Total synthesis has long been depicted as the quest to conquer the structures created by nature, requiring an unflinching, single-minded devotion to the task. The goal is achieved by chemists with grit, strength of will, and a competitive spirit. While there is some truth to this viewpoint, it does not fully capture the rich experiences gained in this research realm. In our lab, strategic planning, improvisation, and conversation have worked in concert to enable progress. This Account summarizes our efforts to synthesize four different bioactive targets: merrilactone A, rocaglamide, phomactin A, and tetrapetalone A. Certain missteps were integral to success in these synthetic projects. As such, we include the hiccups, and their roles in the evolution of the strategies, along with the results that aligned with our expectations.Two of these projects (merrilactone A and rocaglamide) culminated in the total synthesis of the targets. The challenges presented by merrilactone A spawned a new design strategy for pentannulation using Nazarov cyclization chemistry. This work demonstrated that Lewis acid catalysis is often a viable electrocyclization strategy in activated, polarized pentadienyl cation intermediates. We sought to apply the same logic to the rocaglamide target, but precursors we prepared did not behave according to plan. This situation pushed us to adapt our approach to match the innate reactivity of the substrate, resulting in an on-the-spot improvisation that was not only integral to the success of the project but also expanded our understanding of pentadienyl cation chemistry. In the other two projects (phomactin A and tetrapetalone A), we did not complete a total synthesis but did build the polycyclic core of the target. Even though the hetero [4 + 2] cycloaddition plan for assembling the macrocyclic oxadecalin ring system of phomactin A failed, the original experimental design still enabled us to solve the problem. Through a wholly unanticipated series of events, our focus on the oxadecalin ring system primed us for the discovery of a sequential iodoaldol/oxa-Michael sequence, using the original [4 + 2] building blocks. Then, the bridging ring present in phomactin A demanded we implement this sequence in a transannular fashion. Finally, our successful synthesis of the tetrapetalone core was enabled by consultations with others in the community. Each bond formation seemed to require different expertise, and in three separate instances (C-N cross-coupling, diastereoselective ring-closing metathesis, and oxidative dearomatization) synthetic challenges were overcome through conversation and collaboration.In our experience, the amount of creative power we summon during a target synthesis project correlates directly with the magnitude of the structural challenges we face. When reactivity surprises us, we analyze the problem anew, consult with colleagues, and improvise with the tools at hand. The inevitable misbehavior of a complex system is a strong motivating force, and one that has helped to shape our research program for nearly two decades.
Collapse
Affiliation(s)
- Alison J. Frontier
- Department of Chemistry, University of Rochester, 120 Trustee Road, Rochester New York 14611, United States
| | - Paul P. Sinclair
- Department of Chemistry, University of Rochester, 120 Trustee Road, Rochester New York 14611, United States
| |
Collapse
|
5
|
Harneti D, Supratman U. Phytochemistry and biological activities of Aglaia species. PHYTOCHEMISTRY 2021; 181:112540. [PMID: 33130371 DOI: 10.1016/j.phytochem.2020.112540] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Revised: 10/08/2020] [Accepted: 10/08/2020] [Indexed: 05/13/2023]
Abstract
Aglaia is the largest genus in the Meliaceae family (also known as Mahagoni in Indonesia), consisting of over 150 species, of which 65 are indigenous to Indonesia. These species spread through the tropical regions, especially Southeast Asia as well as the Nothern part of Australia, and have been used in traditional medicine for the treatment of several diseases. However, preliminary chemical researches commenced in 1965, where dammarane-type triterpenoids, aglaiol was isolated, and the structure was determined by chemical reaction and spectroscopic methods. Several studies have been carried out on the stembark, bark, leaves, seeds and leaves in the last fifty five years, and about 291 metabolites have been isolated from the sesquiterpenoid, diterpenoid, triterpenoid, limonoid, steroid, lignan, and alkaloid groups, as well as flavagline, which known to be the largest. This specifically amounts to 34% of Aglaia species, reported to show cytotoxic and insecticidal potentials, and also the tendency for use as chemical markers for this species. The extracts and compounds obtained from Aglaia species are evaluated for potential biological activities, including cytotoxicity, insecticidal, anti-inflammatory, antifungal, molluscicidal, antituberculosis and antiviral effects. In addition, flavagline (rocaglamide) derivatives have been confirmed to exhibit exceptional cytotoxicity, and are, thus, considered lead compounds for further development. Therefore, the results support the concept of utilizing Aglaia species as a potential source for the production of biologically active compounds.
Collapse
Affiliation(s)
- Desi Harneti
- Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Jatinangor, 45363, Sumedang, West Java, Indonesia
| | - Unang Supratman
- Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Jatinangor, 45363, Sumedang, West Java, Indonesia; Central Laboratory, Universitas Padjadjaran, Jatinangor, 45363, Sumedang, West Java, Indonesia.
| |
Collapse
|
6
|
Chang LS, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, Shen R, Pan L, Agarwal G, Ren Y, Roberts RD, O'Keefe BR, Kinghorn AD, Collins JM. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Mol Cancer Ther 2020; 19:731-741. [PMID: 31848295 PMCID: PMC7056570 DOI: 10.1158/1535-7163.mct-19-0809] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Revised: 12/02/2019] [Accepted: 12/13/2019] [Indexed: 01/30/2023]
Abstract
Malignant peripheral nerve sheath tumors (MPNST) frequently overexpress eukaryotic initiation factor 4F components, and the eIF4A inhibitor silvestrol potently suppresses MPNST growth. However, silvestrol has suboptimal drug-like properties, including a bulky structure, poor oral bioavailability (<2%), sensitivity to MDR1 efflux, and pulmonary toxicity in dogs. We compared ten silvestrol-related rocaglates lacking the dioxanyl ring and found that didesmethylrocaglamide (DDR) and rocaglamide (Roc) had growth-inhibitory activity comparable with silvestrol. Structure-activity relationship analysis revealed that the dioxanyl ring present in silvestrol was dispensable for, but may enhance, cytotoxicity. Both DDR and Roc arrested MPNST cells at G2-M, increased the sub-G1 population, induced cleavage of caspases and PARP, and elevated the levels of the DNA-damage response marker γH2A.X, while decreasing the expression of AKT and ERK1/2, consistent with translation inhibition. Unlike silvestrol, DDR and Roc were not sensitive to MDR1 inhibition. Pharmacokinetic analysis confirmed that Roc had 50% oral bioavailability. Importantly, Roc, when administered intraperitoneally or orally, showed potent antitumor effects in an orthotopic MPNST mouse model and did not induce pulmonary toxicity in dogs as found with silvestrol. Treated tumors displayed degenerative changes and had more cleaved caspase-3-positive cells, indicative of increased apoptosis. Furthermore, Roc effectively suppressed the growth of osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma cells and patient-derived xenografts. Both Roc- and DDR-treated sarcoma cells showed decreased levels of multiple oncogenic kinases, including insulin-like growth factor-1 receptor. The more favorable drug-like properties of DDR and Roc and the potent antitumor activity of Roc suggest that these rocaglamides could become viable treatments for MPNST and other sarcomas.
Collapse
Affiliation(s)
- Long-Sheng Chang
- Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio.
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio
- Department of Otolaryngology-Head and Neck Surgery, The Ohio State University College of Medicine, Columbus, Ohio
- Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio
| | - Janet L Oblinger
- Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio
| | - Sarah S Burns
- Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio
| | - Jie Huang
- Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio
| | - Larry W Anderson
- Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland
| | - Melinda G Hollingshead
- Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland
| | - Rulong Shen
- Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio
| | - Li Pan
- Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University College of Pharmacy, Columbus, Ohio
| | - Garima Agarwal
- Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University College of Pharmacy, Columbus, Ohio
| | - Yulin Ren
- Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University College of Pharmacy, Columbus, Ohio
| | - Ryan D Roberts
- Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio
| | - Barry R O'Keefe
- Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland
| | - A Douglas Kinghorn
- Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University College of Pharmacy, Columbus, Ohio
| | - Jerry M Collins
- Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland
| |
Collapse
|
7
|
Agarwal G, Wilson JR, Kurina SJ, Anaya-Eugenio GD, Ninh TN, Burdette JE, Soejarto DD, Cheng X, de Blanco EJC, Rakotondraibe LH, Kinghorn AD. Structurally Modified Cyclopenta[ b]benzofuran Analogues Isolated from Aglaia perviridis. JOURNAL OF NATURAL PRODUCTS 2019; 82:2870-2877. [PMID: 31621322 PMCID: PMC6819999 DOI: 10.1021/acs.jnatprod.9b00631] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Four new cyclopenta[b]benzofuran derivatives based on an unprecedented carbon skeleton (1-4), with a dihydrofuran ring fused to dioxanyl and aryl rings, along with a new structural analogue (5) of 5‴-episilvestrol (episilvestrol, 7), were isolated from an aqueous extract of a large-scale re-collection of the roots of Aglaia perviridis collected in Vietnam. Compound 5 demonstrated mutarotation in solution due to the presence of a hydroxy group at C-2‴, leading to the isolation of a racemic mixture, despite being purified on a chiral-phase HPLC column. Silvestrol (6) and episilvestrol (7) were isolated from the most potently cytotoxic chloroform subfraction of the roots. All new structures were elucidated using 1D and 2D NMR, HRESIMS, IR, UV, and ECD spectroscopic data. Of the five newly isolated compounds, only compound 5 exhibited cytotoxic activity against a human colon cancer (HT-29) and human prostate cancer cell line (PC-3), with IC50 values of 2.3 μM in both cases. The isolated compounds (1-5) double the number of dioxanyl ring-containing rocaglate analogues reported to date from Aglaia species and present additional information on the structural requirements for cancer cell line cytotoxicity within this compound class.
Collapse
Affiliation(s)
- Garima Agarwal
- Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, OH 43210, United States
| | - James R. Wilson
- Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, OH 43210, United States
| | - Steven J. Kurina
- Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, United States
| | - Gerardo D. Anaya-Eugenio
- Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, OH 43210, United States
| | - Tran N. Ninh
- Institute of Ecology and Biological Resources, Vietnamese Academy of Science and Technology, Hanoi, Vietnam
| | - Joanna E. Burdette
- Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, United States
| | - Djaja D. Soejarto
- Institute of Ecology and Biological Resources, Vietnamese Academy of Science and Technology, Hanoi, Vietnam
- Science and Technology, Field Museum, Chicago, IL 60605, United States
| | - Xiaolin Cheng
- Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, OH 43210, United States
| | - Esperanza J. Carcache de Blanco
- Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, OH 43210, United States
- Division of Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States
| | | | - A. Douglas Kinghorn
- Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, OH 43210, United States
| |
Collapse
|
8
|
Zhang W, Chu J, Cyr AM, Yueh H, Brown LE, Wang TT, Pelletier J, Porco JA. Intercepted Retro-Nazarov Reaction: Syntheses of Amidino-Rocaglate Derivatives and Their Biological Evaluation as eIF4A Inhibitors. J Am Chem Soc 2019; 141:12891-12900. [PMID: 31310112 PMCID: PMC6693944 DOI: 10.1021/jacs.9b06446] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Rocaglates are a family of natural products isolated from the genus Aglaia which possess a highly substituted cyclopenta[b]benzofuran skeleton and inhibit cap-dependent protein synthesis. Rocaglates are attractive compounds due to their potential for inhibiting tumor cell maintenance in vivo by specifically targeting eukaryotic initiation factor 4A (eIF4A) and interfering with recruitment of ribosomes to mRNA. In this paper, we describe an intercepted retro-Nazarov reaction utilizing intramolecular tosyl migration to generate a reactive oxyallyl cation on the rocaglate skeleton. Trapping of the oxyallyl cation with a diverse range of nucleophiles has been used to generate over 50 novel amidino-rocaglate (ADR) and amino-rocaglate derivatives. Subsequently, these derivatives were evaluated for their ability to inhibit cap-dependent protein synthesis where they were found to outperform previous lead compounds including the rocaglate hydroxamate CR-1-31-B.
Collapse
Affiliation(s)
- Wenhan Zhang
- Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, 590 Commonwealth Avenue, Boston, MA 02215, United States of America
| | - Jennifer Chu
- Department of Biochemistry, McGill University, Montreal, Quebec, Canada, H3G 1Y6
| | - Andrew M. Cyr
- Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, 590 Commonwealth Avenue, Boston, MA 02215, United States of America
| | - Han Yueh
- Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, 590 Commonwealth Avenue, Boston, MA 02215, United States of America
| | - Lauren E. Brown
- Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, 590 Commonwealth Avenue, Boston, MA 02215, United States of America
| | - Tony T. Wang
- Laboratory of Vector-borne Viral Diseases, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20903, USA
| | - Jerry Pelletier
- Department of Biochemistry, McGill University, Montreal, Quebec, Canada, H3G 1Y6
- Department of Oncology, McGill University, Montreal, Quebec, Canada, H3G 1Y6
- Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada, H3G 1Y6
| | - John A. Porco
- Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, 590 Commonwealth Avenue, Boston, MA 02215, United States of America
| |
Collapse
|
9
|
Zhang W, Liu S, Maiga RI, Pelletier J, Brown LE, Wang TT, Porco JA. Chemical Synthesis Enables Structural Reengineering of Aglaroxin C Leading to Inhibition Bias for Hepatitis C Viral Infection. J Am Chem Soc 2019; 141:1312-1323. [PMID: 30590924 PMCID: PMC6583776 DOI: 10.1021/jacs.8b11477] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
As a unique rocaglate (flavagline) natural product, aglaroxin C displays intriguing biological activity by inhibiting hepatitis C viral entry. To further elucidate structure-activity relationships and diversify the pyrimidinone scaffold, we report a concise synthesis of aglaroxin C utilizing a highly regioselective pyrimidinone condensation. We have prepared more than 40 aglaroxin C analogues utilizing various amidine condensation partners. Through biological evaluation of analogues, we have discovered two lead compounds, CMLD012043 and CMLD012044, which show preferential bias for the inhibition of hepatitis C viral entry vs translation inhibition. Overall, the study demonstrates the power of chemical synthesis to produce natural product variants with both target inhibition bias and improved therapeutic indexes.
Collapse
Affiliation(s)
- Wenhan Zhang
- Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, Boston, MA 02215, USA
| | - Shufeng Liu
- Laboratory of Vector-borne Viral Diseases, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20903, USA
| | - Rayelle I. Maiga
- Department of Biochemistry, McGill University, Montreal, Quebec, H3G1Y6, Canada
| | - Jerry Pelletier
- Department of Biochemistry, McGill University, Montreal, Quebec, H3G1Y6, Canada
- Department of Oncology, McGill University, Montreal, Quebec, H3G1Y6, Canada
- Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, Quebec, H3G1Y6, Canada
| | - Lauren E. Brown
- Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, Boston, MA 02215, USA
| | - Tony T. Wang
- Laboratory of Vector-borne Viral Diseases, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20903, USA
| | - John A. Porco
- Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, Boston, MA 02215, USA
| |
Collapse
|
10
|
Bejcek LP, Murelli RP. Oxidopyrylium [5+2] Cycloaddition Chemistry: Historical Perspective and Recent Advances (2008-2018). Tetrahedron 2018; 74:2501-2521. [PMID: 30455508 PMCID: PMC6238658 DOI: 10.1016/j.tet.2018.04.006] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Lauren P Bejcek
- Department of Chemistry, Brooklyn College, City University of New York, Brooklyn, NY, Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY
| | - Ryan P Murelli
- Department of Chemistry, Brooklyn College, City University of New York, Brooklyn, NY, Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY
| |
Collapse
|
11
|
Henkin JM, Ren Y, Soejarto DD, Kinghorn AD. The Search for Anticancer Agents from Tropical Plants. PROGRESS IN THE CHEMISTRY OF ORGANIC NATURAL PRODUCTS 2018; 107:1-94. [PMID: 30178270 DOI: 10.1007/978-3-319-93506-5_1] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Many of the clinically used anticancer agents in Western medicine are derived from secondary metabolites found in terrestrial microbes, marine organisms, and higher plants, with additional compounds of this type being currently in clinical trials. If plants are taken specifically, it is generally agreed that the prospects of encountering enhanced small organic-molecule chemical diversity are better if tropical rather than temperate species are investigated in drug discovery efforts. Plant collection in tropical source countries requires considerable preparation and organization to conduct in a responsible manner that abides by the provisions of the 1992 Rio Convention of Biological Diversity and the 2010 Nagoya Protocol on Access to Genetic Resources. Correct taxonomic identifications and enhanced procedures for processing and documenting plant samples when collected in often difficult terrain are required. Phytochemical aspects of the work involve solvent fractionation, known compound dereplication, preliminary in vitro testing, and prioritization, leading to "activity-guided fractionation", compound structure determination, and analog development. Further evaluation of lead compounds requires solubility, formulation, preliminary pharmacokinetics, and in vivo testing in suitable models. Covering the work of the authors carried out in two sequential multidisciplinary, multi-institutional research projects, examples of very promising compounds discovered from plants acquired from Africa, Southeast Asia, the Americas, and the Caribbean region, and with potential anticancer activity will be mentioned. These include plant secondary metabolites of the diphyllin lignan, cyclopenta[b]benzofuran, triterpenoid, and tropane alkaloid types.
Collapse
Affiliation(s)
- Joshua M Henkin
- Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA
| | - Yulin Ren
- Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, USA
| | - Djaja Djendoel Soejarto
- Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA
| | - A Douglas Kinghorn
- Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
| |
Collapse
|
12
|
Paz BM, Li Y, Thøgersen MK, Jørgensen KA. Enantioselective synthesis of cyclopenta[ b]benzofurans via an organocatalytic intramolecular double cyclization. Chem Sci 2017; 8:8086-8093. [PMID: 29568457 PMCID: PMC5855134 DOI: 10.1039/c7sc03006a] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2017] [Accepted: 09/30/2017] [Indexed: 12/16/2022] Open
Abstract
An enantioselective organocatalytic strategy, combining Brønsted base and N-heterocyclic carbene catalysis in a unique manner, is demonstrated for a concise construction of the privileged cyclopenta[b]benzofuran scaffold, present in many bioactive compounds having both academic and commercial interests. The reaction concept relies on an intramolecular one-pot double cyclization involving a cycle-specific enantioselective Michael addition followed by a benzoin condensation of ortho-substituted cinnamaldehydes. Cyclopenta[b]benzofurans were achieved in moderate to good yields, with excellent stereoselectivities. A proof of principle for a diastereodivergent variation is demonstrated through the synthesis of cyclopenta[b]benzofurans containing two contiguous aromatic substituents in a substitution pattern present in commercial and natural compounds. Furthermore, several transformations have been performed, demonstrating the synthetic utility of the products. Finally, insights into the activation mode and stereoindution models are presented for this new synthetic strategy.
Collapse
Affiliation(s)
- Bruno Matos Paz
- Department of Chemistry , Aarhus University , DK-8000 Aarhus C , Denmark .
| | - Yang Li
- Department of Chemistry , Aarhus University , DK-8000 Aarhus C , Denmark .
| | | | | |
Collapse
|
13
|
Wang W, Clay A, Krishnan R, Lajkiewicz NJ, Brown LE, Sivaguru J, Porco JA. Total Syntheses of the Isomeric Aglain Natural Products Foveoglin A and Perviridisin B: Selective Excited-State Intramolecular Proton-Transfer Photocycloaddition. Angew Chem Int Ed Engl 2017; 56:14479-14482. [PMID: 28950418 PMCID: PMC5876029 DOI: 10.1002/anie.201707539] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2017] [Indexed: 11/10/2022]
Abstract
Selective excited-state intramolecular proton-transfer (ESIPT) photocycloaddition of 3-hydroxyflavones with trans, trans-1,4-diphenyl-1,3-butadiene is described. Using this methodology, total syntheses of the natural products (±)-foveoglin A and (±)-perviridisin B were accomplished. Enantioselective ESIPT photocycloaddition using TADDOLs as chiral hydrogen-bonding additives provided access to (+)-foveoglin A. Mechanistic studies have revealed the possibility for a photoinduced electron-transfer (PET) pathway.
Collapse
Affiliation(s)
- Wenyu Wang
- Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, 590 Commonwealth Avenue, Boston, Massachusetts, 02215, USA
| | - Anthony Clay
- Present address: Department of Chemistry and Center for Photochemical Sciences, Bowling Geen State University, Bowling Green, OH, 43403, USA
| | - Retheesh Krishnan
- Department of Chemistry, Government College for Women, Thiruvananthapuram, 695014, India
| | - Neil J Lajkiewicz
- Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, 590 Commonwealth Avenue, Boston, Massachusetts, 02215, USA
| | - Lauren E Brown
- Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, 590 Commonwealth Avenue, Boston, Massachusetts, 02215, USA
| | - Jayaraman Sivaguru
- Present address: Department of Chemistry and Center for Photochemical Sciences, Bowling Geen State University, Bowling Green, OH, 43403, USA
| | - John A Porco
- Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, 590 Commonwealth Avenue, Boston, Massachusetts, 02215, USA
| |
Collapse
|
14
|
Wang W, Clay A, Krishnan R, Lajkiewicz NJ, Brown LE, Sivaguru J, Porco JA. Total Syntheses of the Isomeric Aglain Natural Products Foveoglin A and Perviridisin B: Selective Excited‐State Intramolecular Proton‐Transfer Photocycloaddition. Angew Chem Int Ed Engl 2017. [DOI: 10.1002/ange.201707539] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Wenyu Wang
- Department of Chemistry, Center for Molecular Discovery (BU-CMD) Boston University 590 Commonwealth Avenue Boston Massachusetts 02215 USA
| | - Anthony Clay
- Present address: Department of Chemistry and Center for Photochemical Sciences Bowling Geen State University Bowling Green OH 43403 USA
| | - Retheesh Krishnan
- Department of Chemistry Government College for Women Thiruvananthapuram 695014 India
| | - Neil J. Lajkiewicz
- Department of Chemistry, Center for Molecular Discovery (BU-CMD) Boston University 590 Commonwealth Avenue Boston Massachusetts 02215 USA
| | - Lauren E. Brown
- Department of Chemistry, Center for Molecular Discovery (BU-CMD) Boston University 590 Commonwealth Avenue Boston Massachusetts 02215 USA
| | - Jayaraman Sivaguru
- Present address: Department of Chemistry and Center for Photochemical Sciences Bowling Geen State University Bowling Green OH 43403 USA
| | - John A. Porco
- Department of Chemistry, Center for Molecular Discovery (BU-CMD) Boston University 590 Commonwealth Avenue Boston Massachusetts 02215 USA
| |
Collapse
|
15
|
|
16
|
Kinghorn AD, DE Blanco EJC, Lucas DM, Rakotondraibe HL, Orjala J, Soejarto DD, Oberlies NH, Pearce CJ, Wani MC, Stockwell BR, Burdette JE, Swanson SM, Fuchs JR, Phelps MA, Xu L, Zhang X, Shen YY. Discovery of Anticancer Agents of Diverse Natural Origin. Anticancer Res 2017; 36:5623-5637. [PMID: 27793884 DOI: 10.21873/anticanres.11146] [Citation(s) in RCA: 74] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Accepted: 09/20/2016] [Indexed: 01/21/2023]
Abstract
Recent progress is described in an ongoing collaborative multidisciplinary research project directed towards the purification, structural characterization, chemical modification, and biological evaluation of new potential natural product anticancer agents obtained from a diverse group of organisms, comprising tropical plants, aquatic and terrestrial cyanobacteria, and filamentous fungi. Information is provided on how these organisms are collected and processed. The types of bioassays are indicated in which initial extracts, chromatographic fractions, and purified isolated compounds of these acquisitions are tested. Several promising biologically active lead compounds from each major organism class investigated are described, and these may be seen to be representative of a very wide chemical diversity.
Collapse
Affiliation(s)
- A Douglas Kinghorn
- College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A. .,Comprehensive Cancer Center, The Ohio State University, Columbus, OH, U.S.A
| | | | - David M Lucas
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, U.S.A.,College of Medicine, The Ohio State University, Columbus, OH, U.S.A
| | | | - Jimmy Orjala
- College of Pharmacy, University of Illinois at Chicago, Chicago, IL, U.S.A
| | - D Doel Soejarto
- College of Pharmacy, University of Illinois at Chicago, Chicago, IL, U.S.A.,Field Museum of Natural History, Chicago, IL, U.S.A
| | - Nicholas H Oberlies
- Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, NC, U.S.A
| | | | - Mansukh C Wani
- Research Triangle Institute, Research Triangle Park, NC, U.S.A
| | - Brent R Stockwell
- Department of Biological Sciences, Columbia University, New York, NY, U.S.A.,Department of Chemistry, Columbia University, New York, NY, U.S.A
| | - Joanna E Burdette
- College of Pharmacy, University of Illinois at Chicago, Chicago, IL, U.S.A
| | - Steven M Swanson
- School of Pharmacy, University of Wisconsin-Madison, Madison, WI, U.S.A
| | - James R Fuchs
- College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A
| | - Mitchell A Phelps
- College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A.,Comprehensive Cancer Center, The Ohio State University, Columbus, OH, U.S.A
| | - Lihui Xu
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, U.S.A
| | - Xiaoli Zhang
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, U.S.A.,College of Medicine, The Ohio State University, Columbus, OH, U.S.A
| | | |
Collapse
|
17
|
Zhou Z, Dixon DD, Jolit A, Tius MA. The Evolution of the Total Synthesis of Rocaglamide. Chemistry 2016; 22:15929-15936. [DOI: 10.1002/chem.201603312] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2016] [Indexed: 12/16/2022]
Affiliation(s)
- Zhe Zhou
- Chemistry Department; University of Hawaii at Manoa; 2545 The Mall Honolulu HI 96822 USA
| | - Darryl D. Dixon
- Chemistry Department; University of Hawaii at Manoa; 2545 The Mall Honolulu HI 96822 USA
| | - Anais Jolit
- Chemistry Department; University of Hawaii at Manoa; 2545 The Mall Honolulu HI 96822 USA
| | - Marcus A. Tius
- Chemistry Department; University of Hawaii at Manoa; 2545 The Mall Honolulu HI 96822 USA
- University of Hawaii; Cancer Center; 701 Ilalo Street Honolulu HI 96813 USA
| |
Collapse
|
18
|
Zhao Q, Abou-Hamdan H, Désaubry L. Recent Advances in the Synthesis of Flavaglines, a Family of Potent Bioactive Natural Compounds Originating from Traditional Chinese Medicine. European J Org Chem 2016. [DOI: 10.1002/ejoc.201600437] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Qian Zhao
- Laboratory of Therapeutic Innovation (UMR 7200); Faculty of Pharmacy; University of Strasbourg-CNRS; Illkirch France
| | - Hussein Abou-Hamdan
- Laboratory of Therapeutic Innovation (UMR 7200); Faculty of Pharmacy; University of Strasbourg-CNRS; Illkirch France
| | - Laurent Désaubry
- Laboratory of Therapeutic Innovation (UMR 7200); Faculty of Pharmacy; University of Strasbourg-CNRS; Illkirch France
- Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry; College of Biotechnology; Tianjin University of Science and Technology; 300457 Tianjin P. R. China
| |
Collapse
|
19
|
Total synthesis of a biotinylated rocaglate: Selective targeting of the translation factors eIF4AI/II. Bioorg Med Chem Lett 2015; 26:262-264. [PMID: 26718843 DOI: 10.1016/j.bmcl.2015.12.045] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2015] [Revised: 10/26/2015] [Accepted: 12/12/2015] [Indexed: 01/09/2023]
Abstract
The total synthesis of a biotinylated derivative of methyl rocaglate is described. This compound was accessed from synthetic methyl rocaglate (2) via formation of the propargyl amide and subsequent click reaction with a biotin azide. Affinity purification revealed that biotinylated rocaglate (8) and methyl rocaglate (2) bind with high specificity to translation factors eIF4AI/II. This remarkable selectivity is in line with that found for the more complex rocaglate silvestrol (3).
Collapse
|
20
|
Zhou Z, Tius MA. Synthesis of Each Enantiomer of Rocaglamide by Means of a Palladium(0)-Catalyzed Nazarov-Type Cyclization. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201501374] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
21
|
Zhou Z, Tius MA. Synthesis of each enantiomer of rocaglamide by means of a palladium(0)-catalyzed Nazarov-type cyclization. Angew Chem Int Ed Engl 2015; 54:6037-40. [PMID: 25824525 DOI: 10.1002/anie.201501374] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Revised: 03/05/2015] [Indexed: 12/29/2022]
Abstract
A recently reported Pd(0)-catalyzed asymmetric Nazarov-type cyclization has been successfully applied in the key step of the first catalytic asymmetric total synthesis of (-)-rocaglamide (natural) and (+)-rocaglamide. The stereochemistry at the C3 position that controls the stereochemistry of all other stereocenters is determined in the cyclization step. This versatile and modular synthesis proceeds from simple reagents.
Collapse
Affiliation(s)
- Zhe Zhou
- Chemistry Department, University of Hawaii at Manoa, 2545 The Mall, Honolulu, HI 96822 (USA)
| | | |
Collapse
|
22
|
Nhu D, Hawkins BC, Burns CJ. Phase Transfer Catalysis Extends The Scope of The Algar–Flynn–Oyamada Synthesis of 3-Hydroxyflavones. Aust J Chem 2015. [DOI: 10.1071/ch14620] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
The Algar–Flynn–Oyamada reaction is the classical method to synthesize 3-hydroxyflavones from chalcones. Despite its relative simplicity, the reaction has several drawbacks including variable and often low product yields. We have found that phase transfer catalysis improves the yields and expands the scope of the Algar–Flynn–Oyamada reaction of a series of 4-benzyloxy-2-hydroxy chalcones.
Collapse
|
23
|
Pan L, Woodard JL, Lucas DM, Fuchs JR, Kinghorn AD. Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species. Nat Prod Rep 2014; 31:924-39. [PMID: 24788392 PMCID: PMC4091845 DOI: 10.1039/c4np00006d] [Citation(s) in RCA: 99] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Covering: 2006 to 2013. Investigations on the chemistry and biology of rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species during the period 2006-2013 are reviewed. Included are new phytochemical studies of naturally occurring rocaglamide derivatives, an update on synthetic methods for cyclopenta[b]benzofurans, and a description of the recent biological evaluation and mechanism-of-action studies on compounds of this type.
Collapse
Affiliation(s)
- Li Pan
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | | | | | | | | |
Collapse
|
24
|
Hawkins BC, Lindqvist LM, Nhu D, Sharp PP, Segal D, Powell AK, Campbell M, Ryan E, Chambers JM, White JM, Rizzacasa MA, Lessene G, Huang DCS, Burns CJ. Simplified silvestrol analogues with potent cytotoxic activity. ChemMedChem 2014; 9:1556-66. [PMID: 24677741 DOI: 10.1002/cmdc.201400024] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2014] [Indexed: 01/11/2023]
Abstract
The complex natural products silvestrol (1) and episilvestrol (2) are inhibitors of translation initiation through binding to the DEAD-box helicase eukaryotic initiation factor 4A (eIF4A). Both compounds are potently cytotoxic to cancer cells in vitro, and 1 has demonstrated efficacy in vivo in several xenograft cancer models. Here we show that 2 has limited plasma membrane permeability and is metabolized in liver microsomes in a manner consistent with that reported for 1. In addition, we have prepared a series of analogues of these compounds where the complex pseudo-sugar at C6 has been replaced with chemically simpler moieties to improve drug-likeness. Selected compounds from this work possess excellent activity in biochemical and cellular translation assays with potent activity against leukemia cell lines.
Collapse
Affiliation(s)
- Bill C Hawkins
- Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052 (Australia); Department of Medical Biology, The University of Melbourne, VIC 3010 (Australia)
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Kogure T, Kinghorn AD, Yan I, Bolon B, Lucas DM, Grever MR, Patel T. Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer. PLoS One 2013; 8:e76136. [PMID: 24086701 PMCID: PMC3784426 DOI: 10.1371/journal.pone.0076136] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2013] [Accepted: 08/23/2013] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND & AIMS Although hepatocellular cancers (HCC) frequently arise in the setting of fibrosis and a hepatic regenerative response requiring new cell growth, therapeutic strategies for these cancers have not targeted protein synthesis. Silvestrol, a rocaglate isolated from Aglaiafoveolata, can inhibit protein synthesis by modulating the initiation of translation through the eukaryotic initiation factor 4A. In this study, we evaluated the therapeutic efficacy of silvestrol for HCC. METHODS The efficacy of silvestrol was examined using human HCC cells in vitro using an orthotopic tumor cell xenograft model in a fibrotic liver. The impact of silvestrol on the liver was assessed in vivo in wild-type mice. RESULTS Silvestrol inhibited cell growth with an IC50 of 12.5-86 nM in four different HCC cell lines. In vitro, silvestrol increased apoptosis and caspase 3/7 activity accompanied by loss of mitochondrial membrane potential and decreased expression of Mcl-1 and Bcl-xL. A synergistic effect was observed when silvestrol was combined with other therapeutic agents, with a dose-reduction index of 3.42-fold with sorafenib and 1.75-fold with rapamycin at a fractional effect of 0.5. In vivo, an antitumor effect was observed with 0.4 mg/kg silvestrol compared to controls after one week, and survival of tumor-bearing mice was improved with a median survival time of 42 and 28 days in the silvestrol and control groups, respectively. The effect on survival was not observed in orthotopic xenografts in non-fibrotic livers. Silvestrol treatment in vivo did not alter liver structure. CONCLUSIONS These data identify silvestrol as a novel, structurally unique drug with potent anticancer activity for HCC and support the potential value of targeting initiation of translation in the treatment of HCC.
Collapse
Affiliation(s)
- Takayuki Kogure
- Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio, United States of America
- Departments of Transplantation and Cancer Biology, Mayo Clinic, Jacksonville, Florida, United States of America
| | - A. Douglas Kinghorn
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, Columbus, Ohio, United States of America
| | - Irene Yan
- Departments of Transplantation and Cancer Biology, Mayo Clinic, Jacksonville, Florida, United States of America
| | - Brad Bolon
- Comparative Pathology and Mouse Phenotyping Shared Resource, Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States of America
| | - David M. Lucas
- Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio, United States of America
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, Columbus, Ohio, United States of America
| | - Michael R. Grever
- Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio, United States of America
| | - Tushar Patel
- Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio, United States of America
- Departments of Transplantation and Cancer Biology, Mayo Clinic, Jacksonville, Florida, United States of America
- * E-mail:
| |
Collapse
|
26
|
Sadlish H, Galicia-Vazquez G, Paris CG, Aust T, Bhullar B, Chang L, Helliwell SB, Hoepfner D, Knapp B, Riedl R, Roggo S, Schuierer S, Studer C, Porco JA, Pelletier J, Movva NR. Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex. ACS Chem Biol 2013; 8:1519-27. [PMID: 23614532 DOI: 10.1021/cb400158t] [Citation(s) in RCA: 92] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Translation initiation is an emerging target in oncology and neurobiology indications. Naturally derived and synthetic rocaglamide scaffolds have been used to interrogate this pathway; however, there is uncertainty regarding their precise mechanism(s) of action. We exploited the genetic tractability of yeast to define the primary effect of both a natural and a synthetic rocaglamide in a cellular context and characterized the molecular target using biochemical studies and in silico modeling. Chemogenomic profiling and mutagenesis in yeast identified the eIF (eukaryotic Initiation Factor) 4A helicase homologue as the primary molecular target of rocaglamides and defined a discrete set of residues near the RNA binding motif that confer resistance to both compounds. Three of the eIF4A mutations were characterized regarding their functional consequences on activity and response to rocaglamide inhibition. These data support a model whereby rocaglamides stabilize an eIF4A-RNA interaction to either alter the level and/or impair the activity of the eIF4F complex. Furthermore, in silico modeling supports the annotation of a binding pocket delineated by the RNA substrate and the residues identified from our mutagenesis screen. As expected from the high degree of conservation of the eukaryotic translation pathway, these observations are consistent with previous observations in mammalian model systems. Importantly, we demonstrate that the chemically distinct silvestrol and synthetic rocaglamides share a common mechanism of action, which will be critical for optimization of physiologically stable derivatives. Finally, these data confirm the value of the rocaglamide scaffold for exploring the impact of translational modulation on disease.
Collapse
Affiliation(s)
- Heather Sadlish
- Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel,
Switzerland
| | | | - C. Gregory Paris
- Novartis Institutes for BioMedical Research, 250 Massachusetts
Avenue Cambridge Massachusetts 02139, United States
| | - Thomas Aust
- Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel,
Switzerland
| | - Bhupinder Bhullar
- Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel,
Switzerland
| | - Lena Chang
- Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel,
Switzerland
| | - Stephen B. Helliwell
- Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel,
Switzerland
| | - Dominic Hoepfner
- Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel,
Switzerland
| | - Britta Knapp
- Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel,
Switzerland
| | - Ralph Riedl
- Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel,
Switzerland
| | - Silvio Roggo
- Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel,
Switzerland
| | - Sven Schuierer
- Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel,
Switzerland
| | - Christian Studer
- Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel,
Switzerland
| | - John A. Porco
- Department of Chemistry, Center for Chemical
Methodology and Library Development, Boston University, Boston, Massachusetts, United States
| | | | - N. Rao Movva
- Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel,
Switzerland
| |
Collapse
|
27
|
Pan L, Acuña UM, Li J, Jena N, Ninh TN, Pannell CM, Chai H, Fuchs JR, Carcache de Blanco EJ, Soejarto DD, Kinghorn AD. Bioactive flavaglines and other constituents isolated from Aglaia perviridis. JOURNAL OF NATURAL PRODUCTS 2013; 76:394-404. [PMID: 23301897 PMCID: PMC3606667 DOI: 10.1021/np3007588] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Eight new compounds, including two cyclopenta[b]benzopyran derivatives (1, 2), two cyclopenta[b]benzofuran derivatives (3, 4), three cycloartane triterpenoids (5-7), and an apocarotenoid (8), together with 16 known compounds, were isolated from the chloroform-soluble partitions of separate methanol extracts of a combination of the fruits, leaves, and twigs and of the roots of Aglaia perviridis collected in Vietnam. Isolation work was monitored using human colon cancer cells (HT-29) and facilitated with an LC/MS dereplication procedure. The structures of the new compounds (1-8) were determined on the basis of spectroscopic data interpretation. The Mosher ester method was employed to determine the absolute configurations of 5-7, and the absolute configuration of the 9,10-diol unit of compound 8 was established by a dimolybdenum tetraacetate [Mo2(AcO)4] induced circular dichroism procedure. Seven known rocaglate derivatives (9-15) exhibited significant cytotoxicity against the HT-29 cell line, with rocaglaol (9) being the most potent (ED50 0.0007 μM). The new compounds 2-4 were also active against this cell line, with ED50 values ranging from 0.46 to 4.7 μM. The cytotoxic compounds were evaluated against a normal colon cell line, CCD-112CoN. In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-κB (p65) inhibitory activity in an ELISA assay.
Collapse
Affiliation(s)
- Li Pan
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Ulyana Muñoz Acuña
- Division of Pharmacy Practice and Administration, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Jie Li
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Nivedita Jena
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Tran Ngoc Ninh
- Institute of Ecology and Biological Resources, Vietnamese Academy of Science and Technology, Hoang Quoc Viet, Cau Giay, Hanoi, Vietnam
| | - Caroline M. Pannell
- Department of Plant Sciences, University of Oxford, South Parks Road, Oxford OX1 3RB, U. K
| | - Heebyung Chai
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - James R. Fuchs
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Esperanza J. Carcache de Blanco
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
- Division of Pharmacy Practice and Administration, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Djaja D. Soejarto
- Program for Collaborative Research in the Pharmaceutical Science and Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States
- Department of Botany, Field Museum of Natural History, 1400 S. Lake Shore Drive, Chicago, Illinois 60605, United States
| | - A. Douglas Kinghorn
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| |
Collapse
|
28
|
Chambers JM, Lindqvist LM, Webb A, Huang DCS, Savage GP, Rizzacasa MA. Synthesis of biotinylated episilvestrol: highly selective targeting of the translation factors eIF4AI/II. Org Lett 2013; 15:1406-9. [PMID: 23461621 DOI: 10.1021/ol400401d] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Silvestrol (1) and episilvestrol (2) are protein synthesis inhibitors, and the former has shown efficacy in multiple mouse models of cancer; however, the selectivity of these potent cytotoxic natural products has not been described. Herein, it is demonstrated that eukaryotic initiation factors eIF4AI/II were the only proteins detected to bind silvestrol (1) and biotinylated episilvestrol (9) by affinity purification. Our study demonstrates the remarkable selectivity of these promising chemotherapeutics.
Collapse
Affiliation(s)
- Jennifer M Chambers
- School of Chemistry, The Bio21 Institute, The University of Melbourne, Melbourne, Victoria 3010, Australia
| | | | | | | | | | | |
Collapse
|
29
|
Liu T, Nair SJ, Lescarbeau A, Belani J, Peluso S, Conley J, Tillotson B, O'Hearn P, Smith S, Slocum K, West K, Helble J, Douglas M, Bahadoor A, Ali J, McGovern K, Fritz C, Palombella VJ, Wylie A, Castro AC, Tremblay MR. Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors. J Med Chem 2012; 55:8859-78. [PMID: 23025805 DOI: 10.1021/jm3011542] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Misregulation of protein translation plays a critical role in human cancer pathogenesis at many levels. Silvestrol, a cyclopenta[b]benzofuran natural product, blocks translation at the initiation step by interfering with assembly of the eIF4F translation complex. Silvestrol has a complex chemical structure whose functional group requirements have not been systematically investigated. Moreover, silvestrol has limited development potential due to poor druglike properties. Herein, we sought to develop a practical synthesis of key intermediates of silvestrol and explore structure-activity relationships around the C6 position. The ability of silvestrol and analogues to selectively inhibit the translation of proteins with high requirement on the translation-initiation machinery (i.e., complex 5'-untranslated region UTR) relative to simple 5'UTR was determined by a cellular reporter assay. Simplified analogues of silvestrol such as compounds 74 and 76 were shown to have similar cytotoxic potency and better ADME characteristics relative to those of silvestrol.
Collapse
Affiliation(s)
- Tao Liu
- Infinity Pharmaceuticals, Inc., 780 Memorial Drive, Cambridge, Massachusetts 02139, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Chambers JM, Huang DCS, Lindqvist LM, Savage GP, White JM, Rizzacasa MA. Total synthesis of 2''',5'''-diepisilvestrol and its C1''' epimer: key structure activity relationships at C1''' and C2'''. JOURNAL OF NATURAL PRODUCTS 2012; 75:1500-1504. [PMID: 22817615 DOI: 10.1021/np300376f] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The first total synthesis of the low-abundance natural product 2''',5'''-diepisilvestrol (4) is described. The key step involved a Mitsunobu coupling between cyclopenta[b]benzofuran phenol 7 and dioxane lactol 6. Deprotection then gave a 1:2.6 ratio of natural product 2''',5'''-diepisilvestrol (4) and its C1 epimer 1''',2''',5'''-triepisilvestrol (15) in 50% overall yield. An in vitro protein translation inhibition assay showed that 2''',5'''-diepisilvestrol (4) was considerably less active than episilvestrol (2), while the unnatural isomer 1''',2''',5'''-triepisilvestrol (15) was essentially inactive, showing that the configuration at C1''' and C2''' has a large effect on the biological activity.
Collapse
Affiliation(s)
- Jennifer M Chambers
- School of Chemistry, The Bio21 Institute, The University of Melbourne, Victoria 3010, Australia
| | | | | | | | | | | |
Collapse
|
31
|
Abstract
RNA helicases unwind their RNA substrates in an ATP-dependent reaction, and are central to all cellular processes involving RNA. They have important roles in viral life cycles, where RNA helicases are either virus-encoded or recruited from the host. Vertebrate RNA helicases sense viral infections, and trigger the innate antiviral immune response. RNA helicases have been implicated in protozoic, bacterial and fungal infections. They are also linked to neurological disorders, cancer, and aging processes. Genome-wide studies continue to identify helicase genes that change their expression patterns after infection or disease outbreak, but the mechanism of RNA helicase action has been defined for only a few diseases. RNA helicases are prognostic and diagnostic markers and suitable drug targets, predominantly for antiviral and anti-cancer therapies. This review summarizes the current knowledge on RNA helicases in infection and disease, and their growing potential as drug targets.
Collapse
Affiliation(s)
- Lenz Steimer
- University of Muenster, Institute for Physical Chemistry, Muenster, Germany
| | | |
Collapse
|
32
|
Abstract
Protein synthesis is a complex, tightly regulated process in eukaryotic cells and its deregulation is a hallmark of many cancers. Translational control occurs primarily at the rate-limiting initiation step, where ribosomal subunits are recruited to template mRNAs through the concerted action of several eukaryotic initiation factors (eIFs). One factor that interacts with both the mRNA and ribosomes, and appears limiting for translation is eIF4F, a complex composed of the cap-binding protein, eIF4E; the scaffold protein, eIF4G; and the ATP-dependent DEAD-box helicase, eIF4A. eIF4E appears to play an important role in tumor initiation and progression since its overexpression can cooperate with oncogenes to accelerate transformation in cell lines and animal models, and its levels are elevated in many human cancers. This, therefore, represents a vulnerability for transformed cells, and presents an opportunity for therapeutic intervention. In this review, we discuss approaches for targeting eIF4F activity.
Collapse
|
33
|
Abstract
A defining feature of many cancers is deregulated translational control. Typically, this occurs at the level of recruitment of the 40S ribosomes to the 5'-cap of cellular messenger RNAs (mRNAs), the rate-limiting step of protein synthesis, which is controlled by the heterotrimeric eukaryotic initiation complex eIF4F. Thus, eIF4F in particular, and translation initiation in general, represent an exploitable vulnerability and unique opportunity for therapeutic intervention in many transformed cells. In this article, we discuss the development, mode of action and biological activity of a number of small-molecule inhibitors that interrupt PI3K/mTOR signaling control of eIF4F assembly, as well as compounds that more directly block eIF4F activity.
Collapse
Affiliation(s)
- Abba Malina
- Department of Biochemistry and McGill University, Montréal, Québec H3G 1Y6, Canada
| | | | | |
Collapse
|
34
|
Magnus P, Freund WA, Moorhead EJ, Rainey T. Formal synthesis of (±)-methyl rocaglate using an unprecedented acetyl bromide mediated Nazarov reaction. J Am Chem Soc 2012; 134:6140-2. [PMID: 22444715 DOI: 10.1021/ja300900p] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
To date the prototype Nazarov cyclization of a cross-conjugated pentadienone to the core structure of the rocaglate natural products has not been successful (9 into 12). It has been found that this conversion can be achieved by the use of acetylbromide in excellent yield and results in a strategically very direct route to these antitumor agents.
Collapse
Affiliation(s)
- Philip Magnus
- Department of Chemistry and Biochemistry, University of Texas at Austin, Austin, Texas 78712, USA.
| | | | | | | |
Collapse
|
35
|
A. Rizzacasa M, Morozova M, Wickremasinghe S. Synthesis of Novel Oligosaccharides Based on 1,4-Dioxanyloxy 3-Oxasugars. HETEROCYCLES 2012. [DOI: 10.3987/com-11-s(p)84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
36
|
Abstract
Small organic molecules derived from higher plants have been one of the mainstays of cancer chemotherapy for approximately the past half a century. In the present review, selected single chemical entity natural products of plant origin and their semi-synthetic derivatives currently in clinical trials are featured as examples of new cancer chemotherapeutic drug candidates. Several more recently isolated compounds obtained from plants showing promising in vivo biological activity are also discussed in terms of their potential as anticancer agents, with many of these obtained from species that grow in tropical regions. Since extracts of only a relatively small proportion of the ca. 300,000 higher plants on earth have been screened biologically to date, bioactive compounds from plants should play an important role in future anticancer drug discovery efforts.
Collapse
Affiliation(s)
- Li Pan
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
| | | | | |
Collapse
|
37
|
Pan L, Chai HB, Kinghorn AD. Discovery of new anticancer agents from higher plants. Front Biosci (Schol Ed) 2012. [PMID: 22202049 DOI: 10.2741/257] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Small organic molecules derived from higher plants have been one of the mainstays of cancer chemotherapy for approximately the past half a century. In the present review, selected single chemical entity natural products of plant origin and their semi-synthetic derivatives currently in clinical trials are featured as examples of new cancer chemotherapeutic drug candidates. Several more recently isolated compounds obtained from plants showing promising in vivo biological activity are also discussed in terms of their potential as anticancer agents, with many of these obtained from species that grow in tropical regions. Since extracts of only a relatively small proportion of the ca. 300,000 higher plants on earth have been screened biologically to date, bioactive compounds from plants should play an important role in future anticancer drug discovery efforts.
Collapse
Affiliation(s)
- Li Pan
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
| | | | | |
Collapse
|
38
|
Ribeiro N, Thuaud F, Nebigil C, Désaubry L. Recent advances in the biology and chemistry of the flavaglines. Bioorg Med Chem 2011; 20:1857-64. [PMID: 22071525 DOI: 10.1016/j.bmc.2011.10.048] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2011] [Revised: 10/04/2011] [Accepted: 10/15/2011] [Indexed: 01/03/2023]
Abstract
The flavaglines are a family of plant natural products that induce potent anticancer and neuroprotective activities. This review summarizes recent synthetic approaches to flavaglines and the current status of their pharmacological properties.
Collapse
Affiliation(s)
- Nigel Ribeiro
- Therapeutic Innovation Laboratory, UMR 7200, CNRS/Université de Strasbourg, 67401 Illkirch, France
| | | | | | | |
Collapse
|
39
|
Tiwari KN, Monserrat JP, de Montigny F, Jaouen G, Rager MN, Hillard E. Synthesis and Structural Characterization of Ferrocenyl-Substituted Aurones, Flavones, and Flavonols. Organometallics 2011. [DOI: 10.1021/om200644e] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
- Keshri Nath Tiwari
- Laboratoire Charles Friedel (LCF), ENSCP Chimie ParisTech, 75005 Paris, France
- CNRS, UMR 7223, 75005 Paris, France
| | - Jean-Philippe Monserrat
- Laboratoire Charles Friedel (LCF), ENSCP Chimie ParisTech, 75005 Paris, France
- CNRS, UMR 7223, 75005 Paris, France
| | - Fréderic de Montigny
- Laboratoire Charles Friedel (LCF), ENSCP Chimie ParisTech, 75005 Paris, France
- CNRS, UMR 7223, 75005 Paris, France
| | - Gérard Jaouen
- Laboratoire Charles Friedel (LCF), ENSCP Chimie ParisTech, 75005 Paris, France
- CNRS, UMR 7223, 75005 Paris, France
| | - Marie-Noelle Rager
- NMR Facility, ENSCP Chimie ParisTech, 11 Rue Pierre et Marie Curie, 75231 Paris Cedex 05, France
| | - Elizabeth Hillard
- Laboratoire Charles Friedel (LCF), ENSCP Chimie ParisTech, 75005 Paris, France
- CNRS, UMR 7223, 75005 Paris, France
| |
Collapse
|
40
|
Saradhi UVRV, Gupta SV, Chiu M, Wang J, Ling Y, Liu Z, Newman DJ, Covey JM, Kinghorn AD, Marcucci G, Lucas DM, Grever MR, Phelps MA, Chan KK. Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry. AAPS J 2011; 13:347-56. [PMID: 21499689 PMCID: PMC3160157 DOI: 10.1208/s12248-011-9273-x] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2011] [Accepted: 03/30/2011] [Indexed: 11/30/2022] Open
Abstract
A sensitive and specific liquid chromatography-tandem mass spectrometry method was developed and validated for the quantification of the plant natural product silvestrol in mice, using ansamitocin P-3 as the internal standard. The method was validated in plasma with a lower limit of quantification of 1 ng/mL, accuracy ranging from 87 to 114%, and precision (coefficient of variation) below 15%. The validated method was used to characterize pharmacokinetics in C57BL/6 mice and metabolism in mouse, human and rat plasma, and liver microsomes. Mice were dosed with silvestrol formulated in hydroxypropyl-β-cyclodextrin via intravenous, intraperitoneal, and oral routes followed by blood sampling up to 24 h. Intraperitoneal systemic availability was 100%, but oral administration resulted in only 1.7% bioavailability. Gradual degradation of silvestrol was observed in mouse and human plasma, with approximately 60% of the parent drug remaining after 6 h. In rat plasma, however, silvestrol was completely converted to silvestric acid (SA) within 10 min. Evaluation in microsomes provided further evidence that the main metabolite formed was SA, which subsequently showed no cytotoxic or cytostatic activity in a silvestrol-sensitive lymphoblastic cell line. The ability of the analytical assay to measure tissue levels of silvestrol was evaluated in liver, brain, kidney, and spleen. Results indicated the method was capable of accurately measuring tissue levels of silvestrol and suggested it has a relatively low distribution to brain. Together, these data suggest an overall favorable pharmacokinetic profile of silvestrol in mice and provide crucial information for its continued development toward potential clinical testing.
Collapse
Affiliation(s)
- U. V. R. Vijaya Saradhi
- />College of Pharmacy, The Ohio State University, 500 W. 12th Avenue, Columbus, Ohio 43210 USA
| | - Sneha V. Gupta
- />College of Pharmacy, The Ohio State University, 500 W. 12th Avenue, Columbus, Ohio 43210 USA
| | - Ming Chiu
- />College of Pharmacy, The Ohio State University, 500 W. 12th Avenue, Columbus, Ohio 43210 USA
| | - Jiang Wang
- />College of Pharmacy, The Ohio State University, 500 W. 12th Avenue, Columbus, Ohio 43210 USA
| | - Yonghua Ling
- />College of Pharmacy, The Ohio State University, 500 W. 12th Avenue, Columbus, Ohio 43210 USA
| | - Zhongfa Liu
- />College of Pharmacy, The Ohio State University, 500 W. 12th Avenue, Columbus, Ohio 43210 USA
| | | | | | - A. Douglas Kinghorn
- />College of Pharmacy, The Ohio State University, 500 W. 12th Avenue, Columbus, Ohio 43210 USA
| | - Guido Marcucci
- />College of Pharmacy, The Ohio State University, 500 W. 12th Avenue, Columbus, Ohio 43210 USA
- />College of Medicine, The Ohio State University, Columbus, Ohio USA
| | - David M. Lucas
- />College of Pharmacy, The Ohio State University, 500 W. 12th Avenue, Columbus, Ohio 43210 USA
- />College of Medicine, The Ohio State University, Columbus, Ohio USA
| | - Michael R. Grever
- />College of Medicine, The Ohio State University, Columbus, Ohio USA
| | - Mitch A. Phelps
- />College of Pharmacy, The Ohio State University, 500 W. 12th Avenue, Columbus, Ohio 43210 USA
- />College of Medicine, The Ohio State University, Columbus, Ohio USA
| | - Kenneth K. Chan
- />College of Pharmacy, The Ohio State University, 500 W. 12th Avenue, Columbus, Ohio 43210 USA
- />College of Medicine, The Ohio State University, Columbus, Ohio USA
| |
Collapse
|
41
|
Abstract
Deregulated translation initiation is implicated extensively in cancer initiation and progression. Several translation initiation factors cooperate with known oncogenes, are elevated in human tumors and have been implicated in drug resistance. Consequently, there is a great deal of interest in targeting this process to develop new chemotherapeutics, especially since clinical trial results have been mixed when targeting upstream pathways, such as the mammalian target of rapamycin. Several inhibitors have been characterized over the last 5 years that target the ribosome recruitment phase (eukaryotic initiation factor [eIF]4E [antisense oligonucleotides and 4EGI-1] or eIF4A [pateamine A, hippuristanol and silvestrol]), some of which demonstrate activity in preclinical cancer models. The promise of these inhibitors as chemotherapeutics highlights the importance of targeting this pathway and supports efforts aimed at identifying the most susceptible targets. In addition, the framework in which translation inhibitors would be best employed (i.e., as single agents or as adjuvant therapy) in the clinic remains to be explored systematically. Small-molecule inhibitors of translation initiation are validating the idea that protein synthesis is a legitimate target for curtailing tumor growth.
Collapse
|
42
|
Kinghorn AD, Pan L, Fletcher JN, Chai H. The relevance of higher plants in lead compound discovery programs. JOURNAL OF NATURAL PRODUCTS 2011; 74:1539-55. [PMID: 21650152 PMCID: PMC3158731 DOI: 10.1021/np200391c] [Citation(s) in RCA: 145] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Along with compounds from terrestrial microorganisms, the constituents of higher plants have provided a substantial number of the natural product-derived drugs used currently in Western medicine. Interest in the elucidation of new structures of the secondary metabolite constituents of plants has remained high among the natural products community over the first decade of the 21st century, particularly of species that are used in systems of traditional medicine or are utilized as botanical dietary supplements. In this review, progress made in the senior author's laboratory in research work on naturally occurring sweeteners and other taste-modifying substances and on potential anticancer agents from tropical plants will be described.
Collapse
Affiliation(s)
- A Douglas Kinghorn
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA.
| | | | | | | |
Collapse
|
43
|
Roche SP, Cencic R, Pelletier J, Porco JA. Biomimetic photocycloaddition of 3-hydroxyflavones: synthesis and evaluation of rocaglate derivatives as inhibitors of eukaryotic translation. Angew Chem Int Ed Engl 2011; 49:6533-8. [PMID: 20687060 DOI: 10.1002/anie.201003212] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Stéphane P Roche
- Department of Chemistry, Center for Chemical Methodology and Library Development (CMLD-BU), Boston University, 590 Commonwealth Avenue, Boston MA, 02215, USA
| | | | | | | |
Collapse
|
44
|
Barjau J, Schnakenburg G, Waldvogel SR. Diversity-Oriented Synthesis of Polycyclic Scaffolds by Modification of an Anodic Product Derived from 2,4-Dimethylphenol. Angew Chem Int Ed Engl 2011; 50:1415-9. [DOI: 10.1002/anie.201006637] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2010] [Indexed: 11/12/2022]
|
45
|
Du Z, Ng H, Zhang K, Zeng H, Wang J. Ionic liquid mediated Cu-catalyzed cascade oxa-Michael-oxidation: efficient synthesis of flavones under mild reaction conditions. Org Biomol Chem 2011; 9:6930-3. [DOI: 10.1039/c1ob06209c] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
46
|
Ebada SS, Lajkiewicz N, Porco JA, Li-Weber M, Proksch P. Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from aglaia species (meliaceae). PROGRESS IN THE CHEMISTRY OF ORGANIC NATURAL PRODUCTS 2011; 94:1-58. [PMID: 21833837 PMCID: PMC4157394 DOI: 10.1007/978-3-7091-0748-5_1] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Sherif S. Ebada
- Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine University of Duesseldorf, Universitaetsstrasse 1, D-40225, Duesseldorf, Germany. Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Ain-Shams University, Organization of African Unity 1, 11566 Cairo, Egypt
| | - Neil Lajkiewicz
- Department of Chemistry and Center for Chemical Methodology and Library Development (CMLD-BU), Boston University, Commonwealth Avenue 590, Boston, MA 02215, USA
| | - John A. Porco
- Department of Chemistry and Center for Chemical Methodology and Library Development (CMLD-BU), Boston University, Commonwealth Avenue 590, Boston, MA 02215, USA
| | - Min Li-Weber
- Tumor Immunology Program (D030), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120, Heidelberg, Germany
| | - Peter Proksch
- Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine University of Duesseldorf, Universitaetsstrasse 1, D-40225, Duesseldorf, Germany
| |
Collapse
|
47
|
Pan L, Kardono LB, Riswan S, Chai H, Carcache de Blanco EJ, Pannell CM, Soejarto DD, McCloud TG, Newman DJ, Kinghorn AD. Isolation and characterization of minor analogues of silvestrol and other constituents from a large-scale re-collection of Aglaia foveolata. JOURNAL OF NATURAL PRODUCTS 2010; 73:1873-8. [PMID: 20939540 PMCID: PMC2993763 DOI: 10.1021/np100503q] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
Two new minor silvestrol analogues [2'''-episilvestrol (1) and 2''',5'''-diepisilvestrol (2)], together with a new 21-norbaccharane-type triterpene (3), two new 3,4-secodammarane triterpenes (4 and 5), and a new eudesmane sesquiterpene (6), as well as nine known compounds, were isolated from a large-scale re-collection of the CHCl(3)-soluble extract of the stem bark of Aglaia foveolata obtained in Kalimantan, Indonesia. The structures of the new compounds were established by interpretation of their spectroscopic data. All of the isolates were tested for cytotoxicity against HT-29 cells. The new silvestrol analogues, 1 and 2, were considerably less active as cytotoxic agents than silvestrol (7) and episilvestrol (5'''-episilvestrol) (8) against this cell line, showing the importance of the configuration at C-2''' in mediating such activity within this compound class. Several of the compounds isolated were also evaluated in a NF-κB (p65) inhibition assay.
Collapse
MESH Headings
- Aglaia/chemistry
- Antineoplastic Agents, Phytogenic/chemistry
- Antineoplastic Agents, Phytogenic/isolation & purification
- Antineoplastic Agents, Phytogenic/pharmacology
- Drug Screening Assays, Antitumor
- HT29 Cells
- Humans
- Indonesia
- Molecular Structure
- NF-kappa B/antagonists & inhibitors
- Nuclear Magnetic Resonance, Biomolecular
- Plant Bark/chemistry
- Resins, Plant/chemistry
- Resins, Plant/isolation & purification
- Sesquiterpenes, Eudesmane/chemistry
- Sesquiterpenes, Eudesmane/isolation & purification
- Sesquiterpenes, Eudesmane/pharmacology
- Triterpenes/chemistry
- Triterpenes/isolation & purification
- Triterpenes/pharmacology
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - A. Douglas Kinghorn
- To whom correspondence should be addressed. Tel:
+1-614-247-8094. Fax: +1-614-247-8081.
| |
Collapse
|
48
|
Kim ES, Kim KH, Park S, Kim JN. Synthesis of dihydroindenofuran scaffold via a Pd-catalyzed 5-endo-trig cyclization/enolate O-alkylation cascade. Tetrahedron Lett 2010. [DOI: 10.1016/j.tetlet.2010.06.127] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
49
|
Roche S, Cencic R, Pelletier J, Porco J. Biomimetic Photocycloaddition of 3-Hydroxyflavones: Synthesis and Evaluation of Rocaglate Derivatives as Inhibitors of Eukaryotic Translation. Angew Chem Int Ed Engl 2010. [DOI: 10.1002/ange.201003212] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
50
|
Lucas DM, Still PC, Pérez LB, Grever MR, Kinghorn AD. Potential of plant-derived natural products in the treatment of leukemia and lymphoma. Curr Drug Targets 2010; 11:812-22. [PMID: 20370646 PMCID: PMC2892601 DOI: 10.2174/138945010791320809] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2009] [Accepted: 01/20/2010] [Indexed: 12/13/2022]
Abstract
Hematologic malignancies account for a substantial percentage of cancers worldwide, and the heterogeneity and biological characteristics of leukemias and lymphomas present unique therapeutic challenges. Although treatment options exist for most of these diseases, many types remain incurable and the emergence of drug resistance is pervasive. Thus, novel treatment approaches are essential to improve outcome. Nearly half of the agents used in cancer therapy today are either natural products or derivatives of natural products. The enormous chemical diversity in nature, coupled with millennia of biological selection, has generated a vast and underexplored reservoir of unique chemical structures with biologic activity. This review will describe the investigation and application of natural products derived from higher plants in the treatment of leukemia and lymphoma and the rationale behind these efforts. In addition to the approved vinca alkaloids and the epipodophyllotoxin derivatives, a number of other plant compounds have shown promise in clinical trials and in preclinical investigations. In particular, we will focus on the discovery and biological evaluation of the plant-derived agent silvestrol, which shows potential for additional development as a new therapeutic agent for B-cell malignancies including chronic lymphocytic leukemia.
Collapse
Affiliation(s)
- David M Lucas
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, 410 W. 12th Avenue, Columbus, OH 43210, USA.
| | | | | | | | | |
Collapse
|